The intrinsic antinociceptive effects of oxycodone appear to be κ-opioid receptor mediated

Pain

Volumn 73, Issue 2, 1997, Pages 151-157

  Ross, Fraser B ^a   Smith, Maree T ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Opioid rcceptors; Antinociception; Intracerebroventricular dosing; Morphine; Norbinaltorphimine; Oxycodone

Indexed keywords

BREMAZOCINE; KAPPA OPIATE RECEPTOR; MORPHINE; NALTRINDOLE; OPIATE ANTAGONIST; OXYCODONE;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL;

ANALGESICS, OPIOID; ANIMALS; INJECTIONS, INTRAVENTRICULAR; MALE; OXYCODONE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, KAPPA;

EID: 0030781043     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(97)00093-6     Document Type: Article

References (33)

1. Beaver, W.T., Wallenstein, S.L., Houde, R.W. and Rogers, A., Comparison of the analgesic effects of oral and intramuscular oxymorphone and morphine in patients with cancer, J. Clin. Pharmacol., 17 (1977) 186-198.
2. Beaver, W.T., Wallenstein, S.L., Houde, R. and Rogers, A., Analgesic studies of codeine and oxycodone in patients with cancer. II. Comparisons of intramuscular oxycodone with intramuscular morphine and codeine, J. Pharmacol. Exp. Ther., 207 (1978) 92-100.
3. Brady, L.S. and Holtzmann, S.G., Analgesic effects of intraventricular morphine and enkephalins in non-dependent and morphine-dependent rats, J. Pharmacol. Exp. Ther., 222 (1982) 190-197.
4. Chen, Z.R., Irvine, R.J., Somogyi, A. and Bochner, F., Mu receptor binding of some commonly used opioids and their metabolites, Life Sci., 48 (1991) 2165-2171.
5. 1 binding assay, Mol. Pharmacol., 34 (1988) 308-317.
6. 3 subtype, J. Pharmacol. Exp. Ther., 251 (1989) 461-468.
7. Cleary, J., Mikus, G., Somogyi, A. and Bochner, F., The influence of pharmacogenetics on opioid analgesia: studies with codeine and oxycodone in the Sprague-Dawley/Dark Agouti rat model
8. D'Amour, F.E. and Smith, D.L., A method for determining loss of pain sensation, J. Pharmacol. Exp. Ther., 72 (1941) 74-79.
9. Emmerson, P.J., Liu, M.-R., Woods, J.H. and Medzihradsky, F., Binding affinity and selectivity at mu, delta and kappa receptors in monkey brain membranes, J. Pharmacol. Exp. Ther., 271 (1994) 1630-1637.
10. Hahn, E.F., Careoll-Buatti, M. and Pasternak, G.W., Irreversible opiate agonists and antagonists: the 14-hydroxydihydromorphinone azines, J. Neurosci., 2 (1982) 572-576.
11. Horan, P., de Costa, B.R., Rice, K.C. and Porreca, F., Differential antagonism of U69,593- and bremazocine-induced antinociception by (-)-UPHIT: evidence of kappa opioid receptor multiplicity in mice, J. Pharmacol. Exp. Ther., 257 (1991) 1154-1161.
12. Jiang, Q., Heyman, J.S. and Porreca, F., Mu antagonist and kappa agonist properties of β-funaltrexamine (β-FNA): long lasting spinal antinociception, NIDA Res. Monogr., 95 (1988) 199-205.
13. Johnson, N. and Pasternak, G.W., Binding of 3H-naloxonazine to rat brain membranes, Mol. Pharmacol., 26 (1984) 477-483.
14. Kaiko, R.F., Benziger, D.P., Fitzmartin, R.D., Burke, B.E., Reder, R.F. and Goldenheim, P.D., Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone, Clin. Pharmacol. Ther., 59 (1996) 52-61.
15. Kalso, E., Vainio, A., Mattila, M.J., Rosenburg, P.H. and Seppala, T., Morphine and oxycodone in the management of cancer pain: plasma levels determined by chemical and radioreceptor assays, Pharmacol. Toxicol., 67 (1990) 322-328.
16. Lacouture, P.G., Iwan, T., Benziger, D., Fitzmartin, R., Cheng, C., Hou, Y. and Kaiko, R.F., Plasma disposition of oxycodone (OC), oxymorphone (OM), and noroxycodone (NO) with long-term controlled-release (CR) oxycodone (Oxycontin™ tablets) dosing, Abst. No. 227, Proc. 8th World Congress on Pain, IASP Press, Seattle, 1996, p. 286.
17. Leighton, G.E., Rodriguez, R.E., Hill, R.G. and Hughs, J., Kappa-opioid agonists produce antinociception after i.v. and i.c.v. but not intrathecal administration in the rat, Br. J. Pharmacol., 93 (1988) 553-560.
18. Leow, K.P. and Smith, M.T., The antinociceptive potencies of oxycodone, noroxycodone and morphine after intracerebroventricular administration to rats, Life Sci., 54 (1994) 1229-1236.
19. 1 sites, Mol. Pharmacol., 25 (1984) 29-37.
20. 3H]ethylketocyclazocine, Life Sci., 42 (1988) 2403-2412.
21. Pasternak, G. and Wood, P., Multiple mu opiate receptors, Life Sci., 38 (1986) 1889-1898.
22. Portoghese, P.S., Sultana, M., Nagase, H. and Takemori, A.E., Application of the message address concept in the design of the highly potent and selective non-peptide delta opioid receptor antagonists, J. Med. Chem., 31 (1988a) 281-282.
23. Portoghese, P.S., Sultana, M. and Takemori, A.E., Naltrindole, a highly selective and potent non-peptide delta opioid receptor antagonist, Eur. J. Pharmacol., 146 (1988b) 185-186.
24. Poyhia, R., and Kalso, E., Antinociceptive effects and central nervous system depression by oxycodone and morphine in rats, Pharmacol. Toxicol., 70 (1992) 125-130.
25. Poyhia, R., Seppala, T., Olkkola, K.T. and Kalso, E., The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects, Br. J. Clin. Pharmacol., 33 (1992) 617-621.
26. Raynor, K., Kong, H., Chen, Y., Yu, L., Bell, G.I. and Reisine, T., Pharmacological characterization of the cloned κ-, δ- and μ-opioid receptors, J. Pharmacol. Exp. Ther., 45 (1994) 330-334.
27. Ross, F.B. and Smith, M.T., The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated, Abst. No. 81, Proc. 8th World Congress on Pain, IASP Press, Seattle, 1996, p. 461.
28. Ross, F.B., Cramond, T. and Smith, M.T., Isolation of the major metabolites of oxycodone in humans, Abst. No. 1415, Proc. 7th World Congress on Pain, IASP Press, Seattle, 1993, p. 531.
29. Smith, M.T., Watt, J.A. and Cramond, T., Morphine-3-glucuronide - a potent antagonist of morphine analgesia, Life Sci., 47 (1990) 579-585.
30. 3H]beta-funaltrexamine to brain slices of morphine-tolerant and -dependent mice, Eur. J. Pharmacol., 149 (1988) 205-212.
31. Takemori, A.E., Ho, B.Y., Naeseth, J.S. and Portoghese, P.S., Nor-binaltorphimine, a highly selective kappa-opioid antagonist, in analgesic and receptor binding assays, J. Pharmacol. Exp. Ther., 246 (1988) 255-258.
32. Von Voightlander, P.F., Lahti, R.A. and Ludens, J.H., U50488H: a selective and structurally non-mu (kappa) opioid agonist, J. Pharmacol. Exp. Ther., 224 (1983) 525-530.
33. Yaksh, T.L. and Harty, G.J., Pharmacology of the allodynia in rats evoked by high dose intrathecal morphine, J. Pharmacol. Exp. Ther., 244 (1987) 501-507.